NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.  [electronic resource] 

 -  Clinical advances in hematology & oncology : H&O  May 2016 
 - 8-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1543-0790 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Chemoradiotherapy<br/>Clinical Trials, Phase I as Topic<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Disease Progression<br/>Humans<br/>Intestinal Neoplasms--diagnosis<br/>Kaplan-Meier Estimate<br/>Neuroendocrine Tumors--diagnosis<br/>Octreotide--administration & dosage<br/>Organometallic Compounds--administration & dosage<br/>Treatment Outcome